S
Surrozen
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific…
About Surrozen
Surrozen is a clinical-stage biotechnology company that specializes in the discovery and development of drug candidates for tissue repair and regeneration. The company's approach is centered on selectively modulating the Wnt pathway, a critical pathway for tissue repair. Surrozen develops tissue-specific antibodies designed to engage the body's own biological repair mechanisms.
The company's current primary focus is on ophthalmology, developing treatments for a broad range of severe eye diseases. By targeting the Wnt pathway, Surrozen aims to provide novel therapeutic options for patients with conditions that lead to tissue damage.
The company's business model involves conducting research and development to advance its drug candidates through the clinical trial process. As a clinical-stage company, its success is tied to the outcomes of these trials and the eventual commercialization of its products. Surrozen's target market includes patients with degenerative diseases, and it collaborates with partners in the biopharmaceutical industry to advance its research and development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Employees
- 69
- Open positions
- 2
- Dealroom signal
- 68.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Regenerative Medicine, Spinout, Biotech and Pharma, SPAC Target, SPAC IPO Announced, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2025 | $175M | — | The Column Group · RA Capital Management · Braidwell · Venrock | ↗ |
| PRIVATE PLACEMENT VCOther financing | Apr 2024 | $18M | — | The Column Group · RA Capital Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Surrozen is 4.2K monthly website visits, up 20% over the last three months. Surrozen's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
The Column Group
Horizons Ventures
Series B and later2 investors entered at this stage
Consonance-HFW Acquisition Corp- CCConsonance Capital
Other known investors12 additional known investors
RA Capital Management
5AM Ventures
Access Biotechnology- APAcuta Capital Partners
Braidwell- KMKalehua Capital Management
Samsara BioCapital
Spruce Street Capital
Stanford University
StemPoint Capital
Venrock
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Surrozen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Surrozen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.